Drug Profile
C 101
Alternative Names: C-101; MyodurLatest Information Update: 27 Apr 2009
Price :
$50
*
At a glance
- Originator CepTor Corporation
- Class
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Muscular dystrophies
Most Recent Events
- 11 Sep 2006 CepTor has filed an IND Complete Response with the FDA in the USA for Duchenne muscular dystrophy
- 25 Apr 2006 Preclinical data from a media release have been added to the Musculoskeletal disorders pharmacodynamics section
- 25 Jan 2006 C 101 has received Orphan Drug Status for Duchenne's and Becker muscular dystrophies in USA